Composition for regulating production of interfering ribonucleic acid
AssigneeWyvern Pharmaceuticals Inc.
InventorBradley G. Thompson
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause a decrease in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a dopamine receptor. In some embodiments of the present disclosure, the target biomolecule is a dopamine receptor such as the D1 dopamine receptor, such as the D2 dopamine receptor, such as the D3 dopamine receptor, or such as the D4 dopamine receptor.
Claims15
A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that comprise a start region, an end region and an insert positioned between the start region and the end region, in which the insert encodes for a sequence of micro-interfering ribonucleic acid (miRNA) that binds to and causes degradation of messenger ribonucleic acid (mRNA) that encodes for a dopamine receptor, wherein the insert sequence comprises 95-100% of the same nucleotide sequence as one of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or SEQ ID NO. 5.
A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that encodes for a sequence of micro-interfering ribonucleic acid (miRNA) that binds to and causes degradation of messenger ribonucleic acid (mRNA) that encodes for a dopamine receptor, wherein the sequence is one of SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, or SEQ ID NO. 9.
Dependencies are inferred from the claim text.